ReviewAntibiotics (Basel, Switzerland)2026
Smart Nano-Antibiotics: AI-Guided Stimuli-Responsive Nanoplatforms for Precision Antimicrobial Therapy.
Review in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Engineering Functional Biomaterials for Targeted and Localized Cancer Drug Delivery: A Structure-Property-Performance Design Perspective.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Biomimetic Coacervate Coatings: From Phase Separation Fundamentals to Advanced Biomedical Applications.Biomimetics (Basel, Switzerland) · 2026Review
- Nanotechnology-Driven Strategies to Combat Antimicrobial Resistance in the One Health Era.Journal of clinical practice and research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The rapid rise of antimicrobial resistance (AMR) has created an urgent need for innovative therapeutic strategies beyond conventional antibiotics. Smart nano-antibiotics have emerged as advanced antimicrobial systems capable of improving drug delivery, enhancing pathogen targeting, overcoming biofilm-associated resistance, and reducing systemic toxicity. This review discusses recent progress in stimuli-responsive nanoplatforms, including pH-responsive, enzyme-responsive, temperature-sensitive, and redox-activated systems for precision antimicrobial therapy. The role of artificial intelligence in nanomaterial design, toxicity prediction, drug release optimization, and personalized treatment development is also critically examined. Furthermore, the review highlights targeted antimicrobial delivery, multifunctional nano-drug combination systems, biosensor integration, and autonomous AI-driven therapeutic platforms for combating multidrug-resistant infections. Current challenges related to toxicity, regulatory limitations, scalability, and AI data reliability are discussed alongside emerging clinical and industrial developments. Smart nano-antibiotics represent a promising next-generation approach for improving precision antimicrobial therapy and addressing the growing global burden of antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.